Precede Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Precede Biosciences's estimated annual revenue is currently $7.8M per year.
- Precede Biosciences's estimated revenue per employee is $155,000
Employee Data
- Precede Biosciences has 50 Employees.
- Precede Biosciences grew their employee count by 61% last year.
Precede Biosciences's People
Name | Title | Email/Phone |
---|
Precede Biosciences Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Precede Biosciences?
We've experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, we've developed a simple blood test to uncover actionable disease-defining transcriptional biology. Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual genes and pathways in diseased tissues from just 1mL of plasma. By partnering with developers of new medicines and advancing our own diagnostic tests, we’re working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that’s precise to the biology of their disease.
keywords:N/AN/A
Total Funding
50
Number of Employees
$7.8M
Revenue (est)
61%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $10.8M | 50 | 0% | N/A |
#2 | $9.8M | 50 | -15% | N/A |
#3 | $3.5M | 50 | 0% | N/A |
#4 | $11M | 50 | 0% | N/A |
#5 | $7.2M | 50 | 4% | N/A |